Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pfizer reaches out to academia—again

Nature Biotechnology volume 29, pages 3–4 (2011)Cite this article

Subjects

For Pfizer, the overall aim in setting up these Global Centers for Therapeutic Innovation (CTIs) is to move novel biotherapeutics rapidly into human clinical trials—each project will aim to deliver a drug through phase 1 testing in five years. Pfizer expects five such initiatives to be up and running in 2011 in the United States, Europe and Asia. Assuming eight projects per CTI, this could bring dozens of differentiated biologics against new targets into the clinical pipeline.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Authors and Affiliations

  1. Cambridge, Massachusetts

    Mark Ratner

Authors
  1. Mark Ratner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ratner, M. Pfizer reaches out to academia—again. Nat Biotechnol 29, 3–4 (2011). https://doi.org/10.1038/nbt0111-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0111-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing